3/24
04:01 pm
mnmd
MindMed Announces New Employee Inducement Grants
Low
Report
MindMed Announces New Employee Inducement Grants
3/17
07:00 am
mnmd
MindMed Appoints Matt Wiley as Chief Commercial Officer
Low
Report
MindMed Appoints Matt Wiley as Chief Commercial Officer
3/7
09:22 am
mnmd
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its price target lowered by analysts at Robert W. Baird from $27.00 to $16.00. They now have an "outperform" rating on the stock.
Low
Report
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its price target lowered by analysts at Robert W. Baird from $27.00 to $16.00. They now have an "outperform" rating on the stock.
3/7
08:13 am
mnmd
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
Medium
Report
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
3/6
07:00 am
mnmd
MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates
Low
Report
MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates
3/4
07:00 am
mnmd
MindMed to Present at Leerink’s Global Healthcare Conference 2025
Low
Report
MindMed to Present at Leerink’s Global Healthcare Conference 2025
2/20
07:00 am
mnmd
MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
Low
Report
MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
2/4
07:00 am
mnmd
MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Medium
Report
MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
1/31
08:09 am
mnmd
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
Medium
Report
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
1/30
07:00 am
mnmd
MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder
Medium
Report
MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder
1/28
07:17 am
mnmd
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $23.00 price target on the stock.
Medium
Report
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $23.00 price target on the stock.
1/7
09:44 pm
mnmd
Why Mind Medicine Stock Is Soaring Today [Yahoo! Finance]
High
Report
Why Mind Medicine Stock Is Soaring Today [Yahoo! Finance]